Y-mAbs Therapeutics Inc (YMAB)
12.09
+0.03
(+0.25%)
USD |
NASDAQ |
Jun 03, 16:00
12.09
0.00 (0.00%)
After-Hours: 20:00
Y-mAbs Therapeutics Cash from Financing (TTM): 0.688M for March 31, 2024
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
March 31, 2024 | 0.688M |
December 31, 2023 | 0.10M |
September 30, 2023 | 0.00 |
June 30, 2023 | 0.052M |
March 31, 2023 | 0.052M |
December 31, 2022 | 0.084M |
September 30, 2022 | 0.184M |
June 30, 2022 | 0.38M |
March 31, 2022 | 0.511M |
December 31, 2021 | 108.31M |
September 30, 2021 | 109.63M |
Date | Value |
---|---|
June 30, 2021 | 109.60M |
March 31, 2021 | 109.47M |
December 31, 2020 | 2.004M |
September 30, 2020 | 135.29M |
June 30, 2020 | 135.07M |
March 31, 2020 | 135.07M |
December 31, 2019 | 134.70M |
September 30, 2019 | -1.842M |
June 30, 2019 | 100.53M |
March 31, 2019 | 100.40M |
December 31, 2018 | 98.76M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-1.842M
Minimum
Sep 2019
135.29M
Maximum
Sep 2020
54.00M
Average
1.346M
Median
Cash from Financing (TTM) Benchmarks
NovaBay Pharmaceuticals Inc | 1.313M |
Palatin Technologies Inc | 14.71M |
iBio Inc | 14.24M |
Theriva Biologics Inc | 0.68M |
Oragenics Inc | 2.096M |